| Literature DB >> 35507867 |
Priscila E Laforet1, Corey H Basch2, Hao Tang3.
Abstract
Over 2 years into the COVID-19 pandemic, information on the safety and efficacy of COVID-19 vaccination, particularly for people in high-risk populations, has become a popular topic of discussion. The purpose of this study was to analyze the content and characteristics of YouTube videos related to COVID-19 vaccination and pregnancy. The 50 most viewed English language videos on pregnancy and COVID-19 vaccination were included in this study. The 50 YouTube videos were viewed 4,589,613 times, with 6% uploaded by consumers, 40% by medical professionals, and 44% by television or internet-based news. Videos from consumer sources more often mentioned a human trial of the COVID-19 vaccine (75% of consumer videos vs. 65% of medical professional videos and 31.8% of television or internet-based news videos, P = .036) and more often mentioned anti-vaccination sentiment, fear, or distrust of the vaccines (37.5% of consumer videos vs 5.0% of medical professional videos and 4.5% of television or internet-based news videos, P = .018). Videos uploaded by medical professionals more often mentioned emergency use of the COVID-19 vaccines (P = .016), passive immunity in general (P = .011), and that the COVID-19 vaccine is either unlikely to or will not cause harm in breastfeeding more often than did videos from consumer or television-based news sources (P = .034). New information regarding COVID-19 vaccination and pregnancy is continuing to emerge, and this study highlights that the information found in the most viewed YouTube videos on this topic can quickly become outdated.Entities:
Keywords: COVID-19; YouTube; misinformation; pregnancy; social media; vaccination
Mesh:
Substances:
Year: 2022 PMID: 35507867 PMCID: PMC9302522 DOI: 10.1080/21645515.2022.2066935
Source DB: PubMed Journal: Hum Vaccin Immunother ISSN: 2164-5515 Impact factor: 4.526
Associations between video upload source and video characteristics, n = 50.
| Video upload source | |||||
|---|---|---|---|---|---|
| | Total (n=50) | Consumer, n=8 | Medical professional, n=20 | Television or internet-based news, n=22 | p-value |
| Video characteristics | N(%) | N (%) | N (%) | ||
| 1.Number of views | 4,589,613 | 277,304 (6.04) | 1,208,967 (26.3) | 3,103,342 (67.6) | |
| 0.425 | |||||
| Mean (SD) | 91,792.26 [359,593.50] | 34,663.00 [28,571.676] | 60,448.35 [72,388.46] | 141,061.00 [540,353.89] | |
| Range | 4,561–2,556,197 | 4,691–75,575 | 5,468–232,107 | 4,561–2,556,197 | |
| 2. Video length | 0.511 | ||||
| Mean (SD) | 9:11 [8:27] | 10:10[08:38] | 09:11[06:16] | 08:51[10:17] | |
| Range, mm:ss | 00:38-41:18 | 01:57-24:52 | 01:56-20:19 | 00:38-41:18 | |
| 3.Video Upload date | 0.591 | ||||
| 04/14/20-09-14-2020 | 7 (14.0) | 1 (12.5) | 4 (20.0) | 2 (9.1) | |
| 09-15-20-02-14-2021 | 43 (86.0) | 7 (87.5) | 16 (80.0) | 20 (90.9) | |
| 4.Mentions need for volunteers | 0.465 | ||||
| Yes | 1 (2.0) | 0 (.0) | 1 (5.0) | 0 (.0) | |
| No | 49 (98.0) | 8 (100.0) | 19 (95.0) | 22 (100.0) | |
| 5. Mentions vaccine was rushed or rapidly developed | 0.091 | ||||
| Yes | 6 (12.0) | 2 (25.0) | 0 (.0) | 4 (18.2) | |
| No | 44 (88.0) | 6 (75.0) | 20 (100.0) | 18 (81.8) | |
| 6. Mentions emergency use | 0.016* | ||||
| Yes | 5 (10.0) | 0 (.0) | 5 (25.0) | 0 (.0) | |
| No | 45 (90.0) | 8 (100.0) | 15 (75.0) | 22 (100.0) | |
| 7. Mentions adverse reactions and/or safety concerns | 0.440 | ||||
| Yes | 16 (32.0) | 4 (50.0) | 5 (25.0) | 7 (31.8) | |
| No | 34 (68.0) | 4 (50.0) | 15 (75.0) | 15 (68.2) | |
| 8. Mentions a specific company manufacturing vaccine | 0.256 | ||||
| Yes | 22 (44.0) | 5 (62.5) | 10 (50.0) | 7 (31.8) | |
| No | 28 (56.0) | 3 (37.5) | 10 (50.0) | 15 (68.2) | |
| 9. Mentions a human trial | 0.036* | ||||
| Yes | 26 (52.0) | 6 (75.0) | 13 (65.0) | 7 (31.8) | |
| No | 24 (48.0) | 2 (25.0) | 7 (35.0) | 15 (68.2) | |
| 10. Mentions an animal trial | 0.512 | ||||
| Yes | 5 (10.0) | 1 (12.5) | 3 (15.0) | 1 (4.5) | |
| No | 45 (90.0) | 7 (87.5) | 17 (85.0) | 21 (95.5) | |
| 11. Mentions anti-vaccination sentiment, fear, or distrust of vaccines | 0.018* | ||||
| Yes | 5 (10.0) | 3 (37.5) | 1 (5.0) | 1 (4.5) | |
| No | 45 (90.0) | 5 (62.5) | 19 (95.0) | 21 (95.5) | |
| 12. Mentions how long immunity will last | 0.560 | ||||
| Yes | 3 (6.0) | 0 (.0) | 2 (10.0) | 1 (4.5) | |
| No | 47 (94.0) | 8 (100.0) | 18 (90.0) | 21 (95.5) | |
| 13. Mentions ability to distribute vaccine widely | 0.465 | ||||
| Yes | 1 (2.0) | 0 (.0) | 1 (5.0) | 0 (.0) | |
| No | 49 (98.0) | 8 (100.0) | 19 (95.0) | 22 (100.0) | |
| 14. Mentions vaccine dosing | 0.348 | ||||
| Yes | 9 (18.0) | 2 (25.0) | 5 (25.0) | 2 (9.1) | |
| No | 41(82.0) | 6 (75.0) | 15 (75.0) | 20 (90.9) | |
| 15. Mentions herd immunity | 0.632 | ||||
| Yes | 3 (6.0) | 0 (.0) | 1 (5.0) | 2 (9.1) | |
| No | 47 (94.0) | 8 (100.0) | 19 (95.0) | 20 (90.9) | |
| 16. Mentions benefits of vaccines | 0.659 | ||||
| Yes | 19 (38.0) | 3 (37.5) | 9 (45.0) | 7 (31.8) | |
| No | 31 (62.0) | 5 (62.5) | 11 (55.0) | 15 (68.2) | |
| 17. Mentions harm of vaccines | 0.086 | ||||
| Yes | 4 (8.0) | 2 (25.0) | 0 (.0) | 2 (9.1) | |
| No | 46 (92.0) | 6 (75.0) | 20 (100.0) | 20 (90.9) | |
| 18. Mentions passive immunity in general | 0.011* | ||||
| Yes | 9 (18.0) | 2 (25.0) | 7 (35.0) | 0 (.0) | |
| No | 41 (82.0) | 6 (75.0) | 13 (65.0) | 22 (100.0) | |
| 19. Mentions COVID-19 vaccine can make someone sterile | 0.091 | ||||
| Yes | 2 (4.0) | 1 (12.5) | 1 (5.0) | 0 (.0) | |
| No | 47 (94.0) | 6 (75.0) | 19 (95.0) | 22 (100.0) | |
| Unsure | 1 (2.0) | 1 (12.5) | 0 (.0) | 0 (.0) | |
| 20. Mentions COVID-19 vaccine unlikely to/will not make someone sterile | 0.150 | ||||
| Yes | 13 (26.0) | 2 (25.0) | 8 (40.0) | 3 (13.6) | |
| No | 37 (74.0) | 6 (75.0) | 12 (60.0) | 19 (86.4) | |
| 21. Mentions vaccine is unlikely to/will not cause harm in breastfeeding | 0.034* | ||||
| Yes | 9 (18.0) | 1 (12.5) | 7 (35.0) | 1 (4.5) | |
| No | 41 (82.0) | 7 (87.5) | 13 (65.0) | 21 (85.5) | |
| 22. Mentions vaccine is safe | 0.795 | ||||
| Yes | 8 (16.0) | 2 (25.0) | 3 (15.0) | 3 (13.6) | |
| No | 36 (72.0) | 6 (75.0) | 14 (70.0) | 16 (72.7) | |
| Likely | 6 (16.0) | 0 (.0) | 3 (15.0) | 3 (13.6) | |
| 23. Mentions having conversation with clinician about getting COVID-19 vaccine | 0.364 | ||||
| Yes | 17 (34.0) | 1 (12.5) | 8 (40.0) | 8 (36.4) | |
| No | 33 (66.0) | 7 (87.5) | 12 (60.0) | 14 (63.6) | |
| 24. Mentions studies didn’t include pregnant patients | 0.745 | ||||
| Yes | 28 (56.0) | 5 (62.5) | 12 (60.0) | 11 (50.0) | |
| No | 22 (44.0) | 3 (37.5) | 8 (40.0) | 11 (50.0) | |
| 25. Mentions American College of Obstetricians and Gynecologists (ACOG) | 0.662 | ||||
| Yes | 14 (28.0) | 2 (25.0) | 7 (35.0) | 5 (22.7) | |
| No | 36 (72.0) | 6 (75.0) | 13 (65.0) | 17 (77.2) | |
| 26. Mentions Society for Maternal and Fetal Medicine | 0.041* | ||||
| Yes | 7 (14.0) | 2 (25.0) | 5 (25.0) | 0 (.0) | |
| No | 43 (86.0) | 6 (75.0) | 15 (75.0) | 22 (100.0) | |
| 27. Mentions passing maternal antibodies through breastmilk/breastfeeding | 0.041* | ||||
| Yes | 7 (14.0) | 2 (25.0) | 5 (25.0) | 0 (.0) | |
| No | 43 (86.0) | 6 (75.0) | 15 (75.0) | 22 (100.0) | |
| 28. Mentions there is not enough data regarding effect of vaccine on breastmilk/nursing mothers | 0.077 | ||||
| Yes | 8 (16.0) | 1 (12.5) | 6 (30.0) | 1 (4.5) | |
| No | 42 (84.0) | 7 (87.5) | 14 (70.0) | 21 (95.5) | |
| 29. Mentions there is not enough data regarding the vaccine and pregnant people | 0.377 | ||||
| Yes | 24 (48.0) | 3 (37.5) | 8 (40.0) | 13 (59.1) | |
| No | 26 (52.0) | 5 (62.5) | 12 (60.0) | 9 (40.9) | |
| 30. Mentions the Syncytin-1 protein | 0.512 | ||||
| Yes | 5 (10.0) | 1 (12.5) | 3 (15.0) | 1 (4.5) | |
| No | 45 (90.0) | 7 (87.5) | 17 (85.0) | 21 (95.5) | |
| 31. Mentions pregnant people who get COVID-19 have more risk to experience a worse outcome | 0.167 | ||||
| Yes | 27 (54.0) | 3 (37.5) | 14 (70.0) | 10 (45.5) | |
| No | 23 (46.0) | 5 (62.5) | 6 (30.0) | 12 (54.5) | |
| 32. Mentions cannot get COVID-19 from vaccine | 0.277 | ||||
| Yes | 3 (6.0) | 1 (12.5) | 2 (10.0) | 0 (.0) | |
| No | 47 (94.0) | 7 (87.5) | 18 (90.0) | 22 (100.0) | |
| 33. Mentions vaccine contains MRNA | 0.352 | ||||
| Yes | 10 (20.0) | 1 (12.5) | 6 (30.0) | 3 (13.6) | |
| No | 40 (80.0) | 7 (87.5) | 14 (70.0) | 19 (86.4) | |
| 34. Mentions a vaccine that contains adenovirus | 0.465 | ||||
| Yes | 1 (2.0) | 0 (.0) | 1 (5.0) | 0 (.0) | |
| No | 49 (98.0) | 8 (100.0) | 19 (95.0) | 22 (100.0) | |
*denotes statistically significant at a p < .05 significance level.